Bloomberg Law
July 28, 2020, 9:25 AM

Insulin, Epinephrine Price Breaks Unlikely Despite Trump Order

Jacquie Lee
Jacquie Lee
Reporter

Insulin and epinephrine costs for most Americans won’t drop under a White House plan to reroute drug discounts directly to patients, health lawyers said.

The community health centers targeted in the order already sell discounted drugs to patients, and the Trump administration may not have the legal power to force deeper discounts at enough pharmacies to make a difference, lawyers said.

President Donald Trump’s July 24 executive order directs federally funded health centers to sell patients insulin and injectable epinephrine at the same discounted price they got it from a drug company. Trump said his goal is to give more ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.